Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 4:24:100468.
doi: 10.1016/j.lanwpc.2022.100468. eCollection 2022 Jul.

Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis

Barnaby Flower  1   2 , Duc Du Hong  1 , Hang Vu Thi Kim  1 , Khue Pham Minh  3 , Ronald B Geskus  1   4 , Jeremy Day  1 , Graham S Cooke  2
Affiliations

Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis

Barnaby Flower et al. Lancet Reg Health West Pac. .

Abstract

Background: Vietnam has one of the greatest disease burdens from chronic viral hepatitis. Comprehensive prevalence data are essential to support its elimination as a public health threat.

Methods: We searched Medline and Embase from 1990 to 2021 for seroprevalence data relating to Hepatitis B (HBV), C (HCV) and D (HDV) in Vietnam. We estimated pooled prevalence with a DerSimonian-Laird random-effects model and stratified study populations into i) low-risk ii) high-risk exposure and iii) liver disease. We further estimated prevalence by decade and region and rates of HIV-coinfection.

Findings: We analysed 72 studies, including 120 HBV, 114 HCV and 23 HDV study populations. Pooled HBV prevalence was low in blood donors (1.86% [1.82-1.90]) but high in antenatal populations (10.8% [10.1-11.6]) and adults in the general population (10.5% [10.0-11.0]). It was similar or modestly increased in groups at highest risk of exposure, suggesting the epidemic is largely driven by chronic infections acquired in childhood. HCV pooled prevalence in the general population was lower than historical estimates: 0.26% (0.09-0.51) have active infection defined by detectable antigen or HCV RNA. In contrast, there is an extremely high prevalence of active HCV infection in people who inject drugs (PWID) (57.8% [56.5-59.1]), which has persisted through the decades despite harm-reduction interventions. HDV appears mainly confined to high-risk groups.

Interpretation: Blood safety has improved, but renewed focus on HBV vaccination at birth and targeted HCV screening and treatment of PWID are urgently required to meet elimination targets. Large cross-sectional studies are needed to better characterize HDV prevalence, but mass screening may not be warranted.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Keywords: Delta virus; HIV; Hepatitis B/epidemiology; Hepatitis C/epidemiology; PWID; Prevalence; Risk factors; Vietnam.

PubMed Disclaimer

Conflict of interest statement

No conflicts declared

Figures

Figure 1
Figure 1
Study selection.
Figure 2
Figure 2
Estimated pooled seroprevalence of HBsAg in low-risk populations.
Figure 3
Figure 3
Estimated pooled seroprevalence of HCV antibody (blue) and HCV antigen/PCR (red) in low-risk populations.
Figure 4
Figure 4
Estimated pooled seroprevalence of HBV in high-risk populations.
Figure 5
Figure 5
Estimated pooled prevalence of HCV antibody (blue) and HCV antigen/PCR (red) in high-risk groups.
Figure 6
Figure 6
HCV antigen prevalence (and antibody where available) in PWID by region. Prevalence pooled for locations with more than one study.
Figure 7
Figure 7
Estimated pooled prevalence of i) HBsAg and ii) HCV antibody in HIV positive populations and iii) HIV co-infection in HCV-antibody positive populations.
Figure 8
Figure 8
Estimated pooled prevalence of HDV antibody and HDV RNA in HBsAg positive cohorts.
See this image and copyright information in PMC

References

    1. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135–184. doi: 10.1016/S2468-1253(18)30270-X. - DOI - PubMed
    1. Palayew A, Razavi H, Hutchinson SJ, Cooke GS, Lazarus J V. Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? Lancet Gastroenterol Hepatol. 2020;5(10):948–953. doi: 10.1016/S2468-1253(20)30011-X. - DOI - PubMed
    1. Khue PM, Thuy Linh NT, Vinh VH, Dung LV. Nguyen Van B. Hepatitis B Infection and Mother-to-Child Transmission in Haiphong, Vietnam: A Cohort Study with Implications for Interventions. Biomed Res Int. 2020;2020 doi: 10.1155/2020/4747965. - DOI - PMC - PubMed
    1. Huy Do S. Epidemiology of Hepatitis B and C Virus Infections and Liver Cancer in Vietnam. Euroasian J hepato-gastroenterology. 2015;5(1):49–51. doi: 10.5005/jp-journals-10018-1130. - DOI - PMC - PubMed
    1. Dao D, Mize G, Pham LT, et al. EASL International Liver Fundation: The Vietnam Viral Hepatitis Alliance (V-VHA) dedicated to viral hepatitis initiatives in Vietnam. In: Vol 41.; 2019:22-25.

LinkOut - more resources